Login to Your Account

Investment Starting to Pay Off

Innovation Gap Begins to Close As New Product Approvals Rise

By Peter Winter

Monday, December 10, 2012

The biopharmaceutical industry is certainly on a productive roll as measured by its output of new medicines. The number of new drug approvals appears to be steadily increasing year-over-year. The rate at which the FDA has approved new molecular entities (NMEs) – including those filed under new drug applications (NDAs) and therapeutic biologics filed under original biologic license applications (BLAs) is already ahead of last year's total of 30 (24 NMEs, and six biologics).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription